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SUMMARY
Transcription activator-like effector nucleases (TALENs) are a new class of engineered nucleases
that are easier to design to cleave at desired sites in a genome than previous types of nucleases.
We report the use of TALENs to rapidly and efficiently generate mutant alleles of 15 genes in
cultured somatic cells or human pluripotent stem cells, the latter of which we differentiated both
the targeted lines and isogenic control lines into various metabolic cell types. We demonstrate
cell-autonomous phenotypes directly linked to disease—dyslipidemia, insulin resistance,
hypoglycemia, lipodystrophy, motor neuron death, and hepatitis C infection. We find little
evidence of TALEN off-target effects, but each clonal line nevertheless harbors a significant
number of unique mutations. Given the speed and ease with which we were able to derive and
characterize these cell lines, we anticipate TALEN-mediated genome editing of human cells
becoming a mainstay for the investigation of human biology and disease.
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INTRODUCTION
The study of human disease has been facilitated by the ability to identify responsible gene
mutations; at the same time, it has been hampered by the lack of an inexhaustible supply of
easily accessible tissues from patients bearing those mutations. Another limitation is that
many gene mutations that would be informative for disease biology if they could be studied
in isolated cells are incompatible with human life (i.e., embryonic lethal). Classical gene
targeting technology via homologous recombination has proven to be an invaluable tool of
experimental biology through its use in mouse embryonic stem cells to generate germline
knockout and knock-in mice; however, its use in mammalian systems has been limited
primarily to studies in mice. In many cases, mice do not faithfully phenocopy human
physiology and disease, e.g., cholesterol metabolism, coronary artery disease, and human
hepatitis C virus (HCV) infection. The emergence of genome editing with engineered
nucleases, as well as human pluripotent stem cell (hPSC) technology and differentiation
protocols to obtain a variety of cell and tissue types in vitro, now make it possible to rapidly
interrogate the effects of genetic modification in otherwise isogenic human model systems.
Transcription activator-like effector nucleases (TALENs) are a new class of engineered
nucleases that due to their modular domain structure have proven more straightforward to
design and construct to perform genome editing than other types of nucleases (Bogdanove
and Voytas, 2011). TALENs are typically designed as a pair that bind to genomic sequences
flanking a target site and generate a double-strand break (DSB), which is repaired by the cell
using either homology-directed repair (HDR) or the error-prone process of non-homologous
end-joining (NHEJ) (Christian et al., 2010; Li et al., 2011; Miller et al., 2011; Hockemeyer
et al., 2011). NHEJ can be exploited to introduce small insertions or deletions (indels)
resulting in frameshift mutations that effectively knock out a protein-coding gene. An
exogenously introduced double-stranded DNA or single-stranded DNA oligonucleotide
(ssODN) can serve as a repair template for HDR to incorporate an alteration into the genome
(Soldner et al., 2011). In principle, TALEN pairs can be generated de novo with standard
molecular biology techniques in a matter of days (Cermak et al., 2011; Sanjana et al., 2012).
To demonstrate the utility, efficiency, and rapidity of TALEN technology in generating
human cellular models with which to derive new biological insights, we created mutations in
15 genes and performed detailed phenotypic analysis of four genes for which novel roles in
disease biology have emerged in recent years—APOB, SORT1, AKT2, and PLIN1.
RESULTS
Modular Assembly and Use of TALENs for Efficient and Rapid Genome Editing
The DNA-binding domain of a TALEN comprises an array of 33- to 35-amino-acid
monomers that are “coded” to recognize and bind specific DNA basepairs in a 1:1 fashion
(Moscou and Bogdanove, 2009; Boch et al., 2009). We built upon previously described
modular Golden Gate metholodogies to allow assembly of multiple DNA fragments in an
ordered fashion (Li et al., 2011; Cermak et al., 2011) such that a single ligation of pre-
assembled tetramers/trimers generates TALENs that recognize any 15-bp recognition site in
the genome (Figure 1 and Figure S1). This assembly method requires only 1–2 days for
completion and is not prone to errors that complicate methods that rely on polymerase chain
reaction (PCR) amplification of monomers. Further, we have developed a set of optimized
vectors and methods for the delivery of TALENs into mammalian cells and, in particular,
hPSCs. Briefly, we transfect or electroporate TALEN pairs into cells and then subject them
to fluorescence activated cell sorting (FACS) 48 hours post-transfection based on
fluorescent marker expression. We replate the sorted cells at low density and allow them to
recover and grow for 1 week, resulting in the formation of distinct single colonies. Colonies
are expanded, genomic DNA purified, and mutations analyzed by PCR, agarose gel
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screening, and Sanger sequencing (Figure 1 and Figure S1). The entire process from start to
finish can be completed in less than one month.
Utilizing these methods we generated TALEN pairs to target 16 distinct sites in 15 genes in
human somatic cell lines, human embryonic stem cell (hESC) lines, or human induced
pluripotent stem cell (iPSC) lines; the alterations included a variety of knockout mutations
as well as a knock-in missense mutation and a functional frameshift mutation (Table 1). We
observed that the efficiency of mutation varied by genomic location as well as among
different cell lines, with indels from NHEJ occurring in roughly 2% to 34% of clones
screened and the efficiency of knock-in by HDR occurring at a frequency of 1.6%. We then
proceeded to perform detailed phenotypic analyses of cells harboring mutations in four
human disease-related genes—APOB, SORT1, AKT2, and PLIN1.
APOB is Required for HCV Replication
APOB, which encodes apolipoprotein B, the core protein of very-low-density lipoprotein
(VLDL) and low-density lipoprotein (LDL) particles that transport cholesterol and
triglycerides from the liver to other tissues via the bloodstream, has been suggested to play a
critical role in hepatitis C virus (HCV) infection. In HCV models using cultured human
HuH-7 hepatoma cells, RNA interference resulting in partial knockdown of APOB
expression has been reported to reduce HCV secretion, albeit not HCV replication (Huang et
al., 2007; Nahmias et al., 2008); however, another report has suggested that apolipoprotein
E, but not apolipoprotein B, is necessary for HCV production (Jiang and Luo, 2009). Thus,
the importance of APOB and precise points of interaction with the HCV lifecycle remain to
be determined. We sought to address this question by generating APOB knockout HuH-7
cells.
The human APOB gene encodes a 512 kDa protein termed apoB-100. We designed a
TALEN pair targeting a site in exon 13 (Figure 2A); frameshift mutations at the site would
generate truncated proteins about 12.5% of the size of apoB-100 (apoB-12.5). We
transfected a clonal line of HuH-7 with high expression of CD81 (a co-receptor for HCV
entry; HuH-7/CD81high) with the APOB TALEN pair. Following FACS with a co-translated
fluorescent marker, replating of sorted cells at limiting dilution, and expansion of single
clones, we found that of 126 screened clones, indels were present in nine clones (Figure
S2A), of which four had exon 13 frameshift mutations in both alleles (Figure 2A).
Compared to wild-type controls from the same set of screened clones, APOB knockout cells
had no detectable intracellular apoB protein, no secreted apoB mass in the media, and <3%
APOB mRNA expression, consistent with nonsense-mediated mRNA decay (Figures 2B,
2C, and 2D).
We infected APOB−/− and wild-type cells with the tissue-culture-infectious HCV strain
JFH-1. The APOB−/− cells had significantly lower intracellular HCV RNA levels (74%
reduction, P = 0.006), with minimal detectable HCV core protein (Figures 2B and 2E).
Reintroduction of apoB-100 protein into the APOB−/− cells by adding LDL particles to the
media, allowing for cellular LDL uptake, resulted in partial restoration of HCV core protein
levels, arguing that the HCV replication defect was the result of loss of APOB function
rather than an off-target effect of the TALENs (i.e., mutagenesis at other sites in the
genome) (Figure 2B). Together, these data suggest that apoB-100 is integral to the HCV
viral lifecycle and that APOB-targeting therapeutics (e.g., mipomersen) may have efficacy
in treating HCV-infected patients.
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Isogenic Disease Models in hPSCs
We found that the karyotype of the HuH-7 cells was severely abnormal (Figure S2B)—
fortuitously, it harbored two APOB alleles, in contrast to SORT1, with at least five alleles—
highlighting the disadvantages of cultured tumor cell lines for rigorous genetic studies.
hPSCs offer several advantages: they can maintain stable genomes with normal karyotypes
while propagated in culture (Figure S2B), preserving correct gene dosage; they can be
differentiated into a variety of cell types, extending studies beyond a single cell type; and
they can yield human cell types that are not available as cultured cell lines, e.g., adipocytes
and motor neurons.
These advantages are mitigated by the significant variability in differentiation capacity and
phenotypic characteristics among different hPSC lines, particularly among iPSC lines. This
variability is attributed to differences in genetic background, in epigenetic state, and in
derivation of the cell lines and adaptation to culture, among other factors. In this variability
lies the potential for confounding of any phenotypic differences observed among
differentiated cell lines generated to serve as disease models or controls—a significant
weakness of studies in which a few iPSC lines from patients are compared with a few iPSC
lines from healthy individuals, as has been the case with most published studies to date,
since any observed differences cannot be reliably attributed to the effects of disease
mutations. We demonstrated this cell line-to-cell line variability by differentiating two hESC
lines, HUES 1 and HUES 9, into hepatocyte-like cells (HLCs) using an adapted protocol
(Si-Tayeb et al., 2010) (Figure S3). We found that there were significant differences in the
amounts of apoB and albumin secreted by the two cell lines and retained in the media
(Figure S4A); when apoB mass was normalized to albumin mass, there was a two-fold
difference between the two lines (P = 0.0001).
Using genome editing to generate isogenic cell lines that differ only with respect to a single
mutation of interest provides a superior study design, since the cell lines would have the
same origin and would thus be matched in genetic background, epigenetic state,
differentiation capacity, derivation and adaptation to culture, etc. This would minimize
confounding of the experiment and allow for more confidence in concluding that any
phenotypic differences are secondary to the mutation. For these reasons, our subsequent
studies were all performed in genome-edited hESCs.
SORT1 Mediates Diverse Cellular Functions in Hepatocytes, Adipocytes, and Neurons
SORT1 (encoding sortilin) was recently discovered by genome-wide association studies to
regulate human blood LDL cholesterol levels and risk for coronary artery disease, via the
modulation of the hepatic secretion of apoB-100-containing particles into the bloodstream;
however, conflicting studies in humans and mice disagree about the direction of the effect of
sortilin on apoB secretion (Musunuru et al., 2010; Kjolby et al., 2010). Human genetic
studies have found that single nucleotide polymorphisms (SNPs) associated with increased
hepatic SORT1 expression are also associated with decreased blood LDL cholesterol levels
(Musunuru et al., 2010). Knockdown and overexpression of Sort1 in mouse liver suggested
that sortilin functions to decrease hepatocyte apoB secretion (Musunuru et al., 2010). In
contrast, a study of Sort1 knockout mice suggested that sortilin increases hepatocyte apoB
secretion (Kjolby et al., 2010).
We targeted exon 2 in the hESC line HUES 1 and, in a single round of TALEN targeting,
generated three clones that were compound heterozygous for frameshift mutations (out of
576 clones screened) and confirmed that they lacked sortilin protein (Figures 3A and 3B). In
parallel, we targeted exon 3 in the hESC line HUES 9 and obtained two knockout clones
(out of 192 clones screened). We differentiated two SORT1−/− and two wild-type HUES 1
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clones or two SORT1−/− and two wild-type HUES 9 clones into hepatocyte-like cells
(HLCs) using an adapted protocol (Si-Tayeb et al., 2010) (Figure S3). Measuring the levels
of apoB as well as albumin and apoA-I (reference controls) secreted from the HLCs and
retained in the media, we found that knockout cells had significantly increased apoB mass
(HUES 1: 117% increase in apoB/albumin ratio, P = 0.04; HUES 9: 65% increase in apoB/
albumin ratio, P = 0.05) (Figure 3C and Figure S4B). We infected knockout HUES 1 HLCs
or HUES 9 HLCs with a lentivirus expressing the SORT1 cDNA or a control lentivirus and
found that reconstitution of SORT1 to the levels observed in wild-type HUES 1 or HUES 9
HLCs resulted in normalization of the apoB mass (Figure 3D and Figure S4C), confirming
that the observed differences in apoB mass are specific to SORT1 function and not the result
of off-target effects. We found that secreted levels of additional hepatic proteins—
ANGPTL4, ANGPTL6, HGF, and FGF-19—did not differ among the various experimental
conditions (Figure S4D), nor did mRNA levels of APOB and other lipid-related genes such
as HMGCR, LDLR, and SREBP1 (Figure S4E). Our data suggest that, in humans, sortilin
acts in hepatocytes to reduce apoB-containing particle levels in the blood, resulting in lower
cholesterol levels and reduced risk of coronary artery disease—consistent with human
genetic studies (Musunuru et al., 2010) and, notably, contradicting the results reported from
Sort1 knockout mice (Kjolby et al., 2010).
SORT1 has also been suggested to play an important role in regulating blood glucose levels
by modulating insulin-dependent translocation of the fat- and muscle-specific glucose
transporter, Glut4, to the plasma membrane via the formation and transport of Glut4 storage
vesicles, based on studies in cultured mouse 3T3-L1 cells (Shi and Kandror, 2005). We
differentiated two SORT1−/− and two wild-type HUES 1 clones into white adipocytes using
a recently published protocol (Ahfeldt et al., 2012), and we observed a substantial increase
in glucose uptake in wild-type adipocytes upon treatment with insulin (63% increase, P =
0.009) but not in SORT1−/− adipocytes (Figure S5A). We infected the knockout adipocytes
with a SORT1 or control lentivirus and found that reconstitution of SORT1 restored insulin-
responsive glucose uptake (60% increase, P = 0.002), confirming that the loss of insulin
response in the knockout adipocytes was specific to SORT1 function and not the result of
off-target effects (Figure 3E and Figure S5B). Thus, SORT1 appears to be critical for
insulin-responsive glucose uptake in human adipocytes and may play a role in insulin
sensitivity in humans.
Finally, SORT1 has also been implicated in the viability and function of neurons (Nykjaer
and Willnow, 2012). In motor neurons, sortilin has been found to regulate neuronal survival
during a temporally and spatially specific period of programmed cell death. Specifically,
induction of motor neuron cell death by the pro-form of brain-derived neurotrophic factor
(proBDNF) has been reported to be dependent on the presence of sortilin (Teng et al., 2005;
Taylor et al., 2011). We differentiated two SORT1−/− and two wild-type HUES 9 clones
into TUJ1+/ISL-1+ motor neurons using an adapted protocol (Di Giorgio et al., 2008;
Chambers et al., 2009) and observed that while both SORT1−/− and wild-type hPSCs
generated similar numbers of motor neurons (Figure S5C), wild-type motor neurons
exhibited a substantial reduction after three days of proBDNF treatment (23% reduction, P =
0.004), whereas SORT1−/− motor neurons were unaffected (Figures 3F and 3G). These data
agree with the reported requirement of SORT1 for proBDNF-induced programmed cell
death in human motor neurons.
AKT2 Regulates Insulin Signaling and Glucose Metabolism in Hepatocytes and Adipocytes
The human AKT2 gene (encoding serine/threonine-protein kinase AKT2/PKBβ) has also
been implicated in the regulation of insulin sensitivity. Loss of function of AKT2 in humans
has been reported to result in severe insulin resistance as well as decreased body fat and
partial lipodystrophy attributed to reduced adipocyte differentiation (George et al., 2004;
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Agarwal and Garg, 2006), and Akt2 knockout mice are resistant to the effects of insulin on
glucose metabolism in liver and muscle and manifest lipoatrophy (Cho et al., 2001; Garofalo
et al., 2003). Recently, three patients with severe hypoglycemia, hypoinsulinemia, and
increased body fat were reported to bear a missense mutation in AKT2, p.Glu17Lys (E17K)
(Hussain et al., 2011). Although the function of the mutant AKT2 E17K protein was
assessed by heterologous overexpression studies in cultured cell lines (HeLa and 3T3-L1)
and interpreted as being activated, the inability to study a physiologically relevant phenotype
(e.g., glucose metabolism) in physiologically relevant tissues (e.g., human liver) precluded
the conclusion that the AKT2 mutation was causal for the metabolic disorder in the patients.
We sought to unequivocally establish a dominant, activated function of the AKT2 E17K
mutant on glucose metabolism by generating an allelic series of isogenic hPSC lines with
wild-type AKT2, knockout of AKT2, or a single AKT2E17K allele. We designed TALENs to
target the site of the E17K mutation in the second coding exon (Figure 4A). In one round of
targeting of HUES 9 cells with the TALEN pair alone, we obtained 17 clones with indels
(out of 192 clones screened), none of which was compound heterozygous for frameshift
mutations. A second round of TALEN targeting with a clone with one frameshift allele
yielded two clones compound heterozygous for frameshift mutations (out of 96 clones
screened). In parallel, we co-electroporated wild-type HUES 9 cells with the TALEN pair
and a 67-nt antisense ssODN harboring the E17K missense variant, yielding three
AKT2E17K heterozygous clones (out of 192 clones screened) (Figure S6A).
We differentiated the allelic series of hPSC clones (two clones each) into HLCs. No AKT2
protein was apparent in the knockout cells, with comparable levels of AKT2 observed in the
wild-type and E17K cells (Figure 4B). We assessed the regulation of the FoxO1
transcription factor, an AKT2 substrate that upon phosphorylation is translocated from the
nucleus to the cytoplasm. In wild-type HLCs, FoxO1 was predominantly nuclear at baseline
and cytoplasmic after insulin stimulation; in AKT2−/− HLCs, predominantly nuclear both at
baseline and after stimulation; in AKT2E17K HLCs, predominantly cytoplasmic both at
baseline and after stimulation (Figure 4C). We assessed glucose production in the allelic
series of HLCs and found that with all three genotypes, addition of dexamethasone and
forskolin to the media dramatically increased glucose production; the further addition of
insulin decreased glucose production in the wild-type HLCs but not in the mutant HLCs
(Figure 4D). In all media conditions, glucose production was significantly higher in AKT2−/
− HLCs and lower in AKT2E17K HLCs compared to wild-type HLCs. Similar trends were
observed in the mRNA expression levels of two genes involved in gluconeogenesis, G6PC
and PCK1 (Figure S6B).
We also differentiated the AKT2 allelic series of hPSC clones into white adipocytes and
found that AKT2−/− adipocytes had significantly decreased triglyceride content (32%
reduction, P = 0.0004) and AKT2E17K adipocytes had significantly increased triglyceride
content (26% increase, P = 0.005) (Figure 4E), consistent with the fat-related phenotypes
observed in patients with AKT2 mutations. We observed a substantial increase in glucose
uptake in wild-type adipocytes upon treatment with insulin (~50% increase in two different
experiments) but, as with SORT1−/− adipocytes, we observed no significant change in
glucose uptake in AKT2−/− adipocytes with insulin (Figure 4F). In contrast, AKT2E17K
adipocytes displayed higher glucose uptake at baseline compared to wild-type adipocytes
(111% increase, P = 0.0001); upon treatment with insulin, there was no further increase in
glucose uptake, presumably because the cells were in a constitutively active state with
respect to insulin signaling (Figure 4F). In the same vein, AKT2E17K adipocytes displayed
substantially increased secretion of inflammatory adipokines such as IL-8 (Figure 4G),
MCP1, and PAI-1 (Figure S6C). Finally, AKT2−/− and AKT2E17K adipocytes showed
decreased and increased secretion of adiponectin, respectively (Figure 4G).
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The opposing effects of the knockout and AKT2E17K alleles, in addition to indicating that
the effects were specific to AKT2 function and not the result of off-target effects, establish
that E17K is indeed a dominant, activating mutation in AKT2 and causal for the
hypoglycemia and increased body fat observed in the three patients.
PLIN1 Frameshift Mutations Dominantly Alter Lipolysis in Adipocytes
PLIN1 encodes the protein perilipin, the most abundant protein coating lipid droplets in
adipocytes, where it is required for droplet formation and maturation, optimal triglyceride
storage, and the release of free fatty acids from the droplet (Brasaemle et al., 2009).
Frameshift mutations in PLIN1 have recently been identified in patients with a novel
autosomal dominant subtype of partial lipodystrophy (Gandotra et al., 2011). The frameshift
mutations found in patients result in a C-terminal elongation of perilipin, with a significantly
altered amino acid sequence. Mice lacking Plin1 exhibit elevated levels of basal lipolysis in
adipocytes (Tansey et al., 2001; Zhai et al., 2010), which has been suggested as the
mechanism by which patients harboring the frameshift mutations develop lipodystrophy
(Gandotra et al., 2011). Mechanistic studies of these disease-causing mutations have been
limited to the overexpression of mutant and wild-type human cDNAs in mouse 3T3-L1-
derived adipocytes, with the conclusion being that wild-type but not mutant PLIN1 is able to
inhibit basal lipolysis (Gandotra et al., 2011).
We designed TALENs to target the site of one of the naturally occurring patient-specific
mutations (Val398fs) in the eighth coding exon of PLIN1 (Figure 5A). In a single round of
targeting of HUES 9 cells we identified 70 mutant clones (out of 293 clones screened). We
characterized two mutant clones, one of which harbors a frameshift mutation that elongates
perilipin to a length of 558 amino acids (designated PLIN1558; wild-type perilipin has 522
amino acids)—very similar to the effect of the naturally occurring Val398fs mutation—and
the other of which has a frameshift resulting in a C-terminal truncation of the protein (415
amino acids; designated PLIN1415) (Figure S7A).
We differentiated the allelic series of hPSCs—wild-type, PLIN1558, and PLIN1415—into
white adipocytes and observed a substantial reduction in the number of lipid droplet-
containing cells as well as smaller lipid droplets in PLIN1558 adipocytes compared to either
wild-type and PLIN1415 cell lines (Figure 5B and Figure S7B). We confirmed the presence
of perilipin protein in the adipocytes by Western blot analysis (Figure 5C and Figure S7C).
We found that the PLIN1558 adipocytes had significantly reduced triglyceride content (38%
reduction compared to wild-type adipocytes, P = 0.0009), whereas the PLIN1415 adipocytes
had similar triglyceride content to wild-type adipocytes (Figure 5D). We also measured
basal and forskolin-stimulated lipolysis and found that both PLIN1558 and PLIN1415
adipocytes had increased basal lipolysis compared to wild-type adipocytes (83% increase, P
= 0.008, and 52% increase, P = 0.04, respectively) (Figure 5E). Interestingly, both the
PLIN1558 and PLIN1415 mutations resulted in increased lipolysis, though the effect was
more marked with the PLIN1558 mutation; furthermore, there were significant differences in
the expression levels of adipocyte-specific genes between the PLIN1558 and PLIN1415 cells,
underscoring that the two different frameshifts (one leading to elongation of perilipin, the
other to truncation) have distinct functional consequences (Figure S7D). Together, these
data point to the C-terminal elongated form of perilipin, via a frameshift similar to naturally
occurring mutations in lipodystrophy patients, acting in a dominant fashion to alter lipolysis
and reduce triglyceride storage and lipid droplet formation in human adipocytes.
TALENs Exhibit Minimal Off-Target Effects, but Sequence Variants Abound
As the extent of off-target effects of TALENs (i.e., mutagenesis at other sites in the genome)
in hPSCs remains to be defined, we performed exome sequencing of six cell lines: the
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parental HUES 1 cell line (clone X); the three SORT1 knockout HUES 1 clones (A–C in
Figure 3A); a control HUES 1 clone that had been grown in parallel with the SORT1
knockout clones (i.e., had been exposed to the SORT1 exon 2 TALEN pair but retained two
wild-type alleles; clone W); and a clone that had been targeted in the CELSR2 gene with a
different TALEN pair (clone Y). It should be noted that TALENs virtually always induce
indels by NHEJ, rather than single nucleotide variants (SNVs). Restricting our analysis to
novel DNA sequence variants not found in the parental HUES 1 cell line, we identified the
known on-target indels in SORT1 in clones A–C; otherwise, we identified just two indels in
the exome, a 4-bp deletion in clone C in the coding sequence of LARP6, resulting in a
predicted frameshift mutation, and a 1-bp deletion in clone Y in an intron near an exon-
intron boundary of LUC7L3 (Table 2). Neither of these sites is flanked by sequences
resembling predicted TALEN binding sites, arguing against (but not ruling out) the indels
being TALEN-mediated off-target effects. More noteworthy were the 35 Sanger sequencing-
confirmed SNVs we discovered across the five experimental and control clones (Table 2).
None of these SNVs lay near predicted off-target TALEN binding sites (see below). It is
more likely that these SNVs represent intrinsic and perhaps unavoidable heterogeneity
among single cell clones of the original pool of HUES 1 cells. Arguing in favor of this
interpretation, several of the SNVs were shared by both experimental and control clones,
implying a common clonal origin within the original pool of HUES 1 cells. The functional
significance of these SNVs is unclear, but the majority resulted in missense mutations, and
at least one lay in a well-established disease gene (DMD, responsible for Duchenne
muscular dystrophy).
We also performed whole-genome sequencing of the same six cell lines. Because the
sequencing was performed at low coverage (6–12× coverage on average), it was not possible
to perform de novo genome assembly and ascertain all sequence variation among the
genomes. Instead, we used the sequencing data to interrogate the sites in the genome at
which one or the other TALEN of the SORT1 exon 2 TALEN pair would be most likely to
bind based on a weighted TAL monomer–nucleotide association probability matrix
developed by Doyle et al. (2012) and, thus, be most likely to induce an off-target sequence
change. About 100,000 potential off-target genomic sites were identified; we screened all of
these sites for evidence of nearby indels. Besides the known SORT1 indels in clones A–C,
we identified no indels passing our criteria.
Thus, although we are not able to completely rule out TALEN off-target effects, we
conclude that off-target indels rarely occur based on the results of the exome and whole-
genome sequence analyses. However, extrapolating to the entire genome, we expect that
each clonal cell line harbors hundreds of SNVs that distinguish it from other cell lines
derived from the same pool of parental cells. Thus, it may be virtually impossible to derive
truly isogenic cell lines, even with the minimized manipulation of cells entailed by our
genome editing system.
DISCUSSION
With our studies, we have used human model systems to generate strong evidence that
apoB-100 is critical for HCV replication in human hepatocytes; that sortilin reduces apoB
secretion by human hepatocytes, facilitates insulin-mediated glucose uptake by human
adipocytes, and is necessary for proBDNF-mediated motor neuron apoptosis; that AKT2
E17K is a gain-of-function mutation that leads to reduced glucose production in human
hepatocytes and increased triglyceride content in human adipocytes; and that PLIN1
frameshift mutations increase basal lipolysis in human adipocytes. More generally, these
findings highlight the various types of studies to which genome editing in human cells may
be applied to obtain novel biological insights.
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We note that genome-editing technology is rapidly advancing, and we anticipate that
improvements in the engineering of TALENs will continue to make genome editing more
rapid and efficient. Indeed, since we established our system, high-throughput automated
assembly methods have been reported (Reyon et al., 2012; Briggs et al., 2012), as well as the
characterization of TAL monomers with improved nucleotide-binding specificity (Streubel
et al., 2012; Cong et al., 2012). While our specific TALEN assembly platform does not
incorporate these latest advancements, in principle any up-to-date assembly platform that is
paired to a delivery methodology similar to ours should be able to achieve efficient genome
editing on a timescale of less than a month.
Whatever the assembly platform, our studies suggest that TALENs incur a low burden of
off-target effects but that there is nevertheless significant clone-to-clone genetic variation in
the form of SNVs; even if not secondary to TALEN use, they cannot be ignored. The ease
and rapidity of TALEN-mediated genome editing allows for rigorous study designs that can
alleviate any concerns about off-target effects or other potential confounding by clonal
sequence variation. As we have demonstrated with SORT1, it is straightforward to (1)
generate multiple distinct mutant cell lines with each TALEN pair, (2) use distinct TALEN
pairs to target different sites in a gene, (3) generate mutant clones in different cell lines with
different genetic backgrounds, and (4) perform reconstitution experiments in knockout
clones. Having used all of these approaches, we are able to conclude with great confidence
that the observed cellular phenotypes are indeed related to SORT1 function. We suggest that
using at least one of these approaches should become de rigeur for future genetic studies in
order to minimize confounding by clonal sequence variation.
With the ability to use TALENs to readily insert specific gene variants into cells, the current
enthusiasm for the generation and comparison of “disease” iPSC lines from patients with
genetic disorders and “control” iPSC lines from unmatched healthy individuals should shift
to the use of genome editing to engineer isogenic cell lines with and without disease
mutations. The time it takes to recruit a patient for the donation of tissue from which to
make iPSCs (assuming such a patient is readily accessible, which may not be the case for
rare disorders), to perform reprogramming to derive iPSC clones, to perform quality control
to identify clones that are pluripotent and that will readily differentiate into the desired cell
type, and then to undertake differentiation and phenotypic studies—in the absence of
isogenic control cell lines—is a minimum of six months and usually longer. Within a shorter
timeframe, we have found it to be quite feasible to use TALENs to edit a well-characterized
and pre-validated (with respect to differentiation capacity) hPSC line and yield both mutant
cell lines and isogenic control cell lines—allowing for a more rigorous study design—and to
undertake differentiation and phenotypic studies, without any need for patient contact.
The potential advantages offered by pre-validated wild-type cell lines notwithstanding, there
are many disorders for which genetic background (i.e., modifier genes) plays a significant
role in determining whether disease mutations result in clinical phenotypes. In these cases, it
will be important to use iPSC lines from patients with clinically apparent disease in order to
have cell lines with the correct genetic backgrounds for complete disease penetrance
(whereas wild-type cell lines may have non-permissive genetic backgrounds). Genome
editing with TALENs could be readily applied to patient-specific iPSC lines to “cure”
disease mutations and generate appropriate isogenic control lines. Indeed, the most robust
possible study design may be to assess both the effect of inserting a disease mutation into a
wild-type cell line—thereby testing for sufficiency of the mutation for disease—and the
effect of removing a disease mutation from a patient-specific iPSC line—thereby testing for
necessity of the mutation for disease. Certainly the rapidity and efficiency of genome editing
with TALENs should make it feasible to test the effects of a disease mutation in a variety of
genetic backgrounds.
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Finally, genome editing potentially allows for the interrogation of a large number of DNA
sequence variants, such as those now emerging from next-generation sequencing studies of
human populations, on a single genetic background. Creating a robust allelic series of
isogenic cell lines represents an approach that hitherto has only been possible in non-
mammalian organisms. Such studies will represent a significant advance in our ability to
dissect genotype-phenotype relationships and thereby better elucidate human biology and
disease.
EXPERIMENTAL PROCEDURES
TALEN construction
TALEN genomic binding sites were chosen to be 15 bp in length or, in a few cases, 13 bp in
length such that the target sequence between the two binding sites was between 14 and 18
bp in length; each binding site was anchored by a preceding T base in position “0” as has
been shown to be optimal for naturally occurring TAL proteins (Moscou and Bogdanove,
2009; Boch et al., 2009). A library of 832 tetramer or trimer TAL repeats were constructed
using methods based on the PCR-based protocol of Zhang et al. (2011); these multimers
were designed to have complementary sticky ends when digested out of library plasmids
with the type IIs restriction enzyme BsmBI. As outlined in Figure 1, multimers were
assembled into an array and subcloned into a full-length TALEN harboring, in order: a N-
terminal FLAG tag, a nuclear localization signal, the N-terminal portion of the TALE
PthXo1 from the rice pathogen X. oryzae pv. oryzae (a kind gift of Dr. Daniel Voytas,
University of Minnesota) lacking the first 176 amino acids (after Miller et al., 2011), the
engineered TAL repeat array, the following 63 amino acids from the corresponding C-
terminal portion of PthXo1 (after Miller et al., 2011), and one of two enhanced FokI
domains. The FokI domains used were obligate heterodimers with both the Sharkey (Guo et
al., 2010) and ELD:KKR (Doyon et al., 2011) mutations to enhance cleavage activity,
engineered by PCR. Each TALEN was in a plasmid with the CAG promoter for optimal
expression in hPSCs, with the TALEN being coexpressed with a fluorescent marker
[enhanced green fluorescent protein (EGFP), mCherry (Clontech), or turbo red fluorescent
protein (tRFP; Evrogen)] via an intervening viral 2A sequence. The generic TALEN protein
sequences are shown in Figure S1A. All reagents, protocols, and plasmid sequences needed
to generate TALENs and perform genome editing by the methods described in this
manuscript will be available to academic researchers through Addgene (http://
www.addgene.org/TALEN_genome_editing_collection).
Cell culture, transfection/electroporation, and sorting
HuH-7/CD81high cells were grown in adherent culture in DMEM High Glucose containing
glutamine and pyruvate (Invitrogen) and supplemented with 10% FBS and penicillin/
streptomycin. Transfection of the plasmids expressing the APOB TALEN pair into HuH-7
cells was performed using Fugene 6 (Roche) in 10-cm tissue culture plates according to
manufacturer instructions. HUES 1 and HUES 9 cells (Cowan et al., 2004) were grown in
feeder-free adherent culture in chemically defined mTeSR1 (STEMCELL Technologies)
supplemented with penicillin/streptomycin on plates pre-coated with Geltrex matrix
(Invitrogen). The cells were disassociated into single cells with Accutase (Invitrogen), and
10 million cells were electroporated with 50 µg of the TALEN pair (25 µg of each plasmid),
or with a mix of 30 µg of the TALEN pair (15 µg of each plasmid) and 30 µg of the ssODN
(5’-CAGGA AGTAC CGTGG CCTCC AGGTC TTGAT GTACT TACCT GAAAT
GAGGC AGGAA GGGAG GGAGA GA-3’), in a single cuvette and replated as previously
described (Schinzel et al., 2011). The cells were collected from the culture plates 48 hours
post-transfection or post-electroporation by trypsin or Accutase treatment, respectively, and
resuspended in PBS. Cells expressing green and/or red fluorescent markers were collected
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by FACS (FACSAria II; BD Biosciences) and replated on 10-cm tissue culture plates at
15,000 cells/plate to allow for recovery in growth media.
Isolation of targeted clonal cell populations
Post-FACS, the cells were allowed to recover for 7–10 days, after which single colonies
were manually picked and dispersed and replated individually to wells of 96-well plates.
Colonies were allowed to grow to near confluence over the next 7 days, at which point they
were split using trypsin (for HuH-7 cells) or Accutase (for hESCs) and replica-plated to
create a working stock and a frozen stock. The working stock was grown to confluence.
Genomic DNA was extracted in 96-well format from working stocks in lysis buffer (10 mM
Tris pH 7.5, 10 mM EDTA, 10 mM NaCl, 0.5% Sarcosyl) containing proteinase K at 56°C
overnight in a humidified chamber. Genomic DNA was precipitated by addition of 95%
ethanol containing 75 mM NaCl for 1 hr at room temperature. The DNA was then washed 2
times in 70% ethanol, allowed to dry at room temperature, and then resuspended in
nuclease-free water.
Genotyping at the TALEN target site was then performed for each sample by PCR
amplication (94°C 30 sec; 56°C 30 sec; 68°C 30 sec) using FastStart Taq (Roche) and a
primer pair designed to yield small amplicons (~150–200 bp) around the target site.
Amplicons were subjected to electrophoresis on 2.5% agarose gels to discriminate clones
with indels, with positive clones having a band or bands visibly shifted in size from the
baseline (see Figure S1B and Figure S6A for examples); for AKT2 E17K candidate clones,
the amplicons were digested with RsaI for 1 hr and subjected to electrophoresis, with
positive clones displaying cleavage products (Figure S6A). For a subset of the potentially
positive clones, PCR amplicons were subcloned using the TOPO TA Cloning Kit
(Invitrogen) and subjected to numerous sequence reads to confirm the presence of mutant
alleles; in a similar fashion, a subset of the potentially negative clones were confirmed to be
wild-type. Clones with confirmed compound heterozygous mutant alleles (or the AKT2
E17K mutation) or confirmed to be wild-type were retrieved from the frozen stocks and
expanded for further experiments. When no compound heterozygous clones were identified,
a heterozygous clone with one mutant allele was expanded and subjected to a second round
of TALEN targeting.
Differentiation of hPSCs into HLCs, white adipoctyes, and motor neurons
Differentiation was performed following the protocols of Si-Tayeb et al. (2010), Ahfeldt et
al. (2012), and Di Giorgio et al. (2008) and Chambers et al., (2009). Details are given in
Supplemental Experimental Procedures.
Enzyme-linked immunosorbent assays (ELISAs), immunocytochemistry, and Western blot
analysis
These procedures were performed using standard methods. Details are given in
Supplemental Experimental Procedures.
Glucose production, glucose uptake, triglyceride content, and lipolysis assays
Glucose production and glucose uptake were measured using protocols adapted from
Hagiwara et al. (2012) and Ahfeldt et al. (2012), respectively. Details of the various
procedures are given in Supplemental Experimental Procedures.
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)
qRT-PCR was performed using standard methods. Details and oligonucleotide sequences are
given in Supplemental Experimental Procedures.
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HCV infection of HuH-7 cells
Details are given in Supplemental Experimental Procedures.
Exome and whole-genome sequence analyses
Exome sequencing and whole-genome sequencing were performed as previously described
(Gnirke et al., 2009; Stransky et al., 2011). Procedural and analytical details are given in
Supplemental Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• A system for efficient and rapid genome editing with TALENs
• Generation of isogenic human cellular models of disease
• Identification of disease-associated phenotypes in multiple human cell types
• Minimal TALEN off-target effects, but significant clone-to-clone sequence
variation
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Figure 1. Schematic of System for Efficient and Rapid Genome Editing with TALENs
GFP = green fluorescent protein; RFP = red fluorescent protein. See also Figure S1.
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Figure 2. APOB is Important for HCV Replication
(A) Generation of APOB knockout HuH-7 clones with TALENs targeting exon 13. Boxes
indicate the TALEN binding sites. Deletions, insertions, and duplications in the two alleles
of each clone are indicated. The 26-bp insertion and 8-bp duplication (asterisk) in clone A
are 5’-GAGTCGCTTCTCCGGGAGATAAGTCA-3’ and 5’-GACTGGCT-3’, respectively.
(B) Left panel, Western blot using whole cell lysates from two wild-type and four knockout
HuH-7 cell lines (clones A–D). Right panel, Western blot from a wild-type clone and a
knockout clone (clone A) infected with or without JFH-1 virus and incubated with or
without LDL particles. The same wild-type clone and knockout clone (clone A) were used
for all subsequent experiments.
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(C) Left panel, apoB ELISAs performed on conditioned media from cells; values are
normalized to level from wild-type clone. Right panel, APOB mRNA expression by qRT-
PCR from whole cell lysates; expression is indicated as fold change of 2−ΔΔCt with
reference to 18S rRNA, normalized to level in wild-type clone.
(D) Immunocytochemistry for apoB.
(E) HCV RNA levels by qRT-PCR from clones infected with JFH-1 virus; expression is
indicated as fold change of 2−ΔΔCt with reference to GAPDH, normalized to level in wild-
type clone.
Error bars show s.e.m. from experiments with biological replicates, N = 3. P values
calculated with unpaired t test. See also Figure S2.
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Figure 3. SORT1 Reduces Hepatocyte Secreted ApoB Mass, is Important for Insulin-Responsive
Glucose Transport in Adipocytes, and Mediates proBDNF-Induced Motor Neuron Death
(A) Generation of SORT1 knockout hPSC clones with TALENs targeting exon 2 or exon 3.
Boxes indicate the TALEN binding sites. Deletions and insertions in the two alleles of each
clone are indicated. The 17-bp insertion (asterisk) in clone B is 5’-
TGCTATCTCCAACCAGG-3’.
(B) Western blot for sortilin and qRT-PCR for SORT1 mRNA in wild-type and knockout
HUES 1 clones (clones A–C); mRNA expression is indicated as fold change of 2−ΔΔCt with
reference to 18S rRNA, normalized to mean level in wild-type clones.
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(C) Albumin and apoB mass measured by ELISA in media collected from wild-type and
knockout HLCs (two clones each; A and B for HUES 1, D and E for HUES 9), normalized
to mean levels in wild-type HLCs. N = 3 for HUES 1, N = 6 for HUES 9.
(D) Western blots of lysates and ELISAs in media from wild-type and knockout HLCs (one
clone each, A for HUES 1; two clones each, D and E for HUES 9) infected with SORT1- or
GFP-expressing lentivirus, normalized to mean levels in wild-type HLCs. N = 2 for HUES
1, N = 6 for HUES 9.
(E) Ratios of glucose uptake to total protein content in wild-type and knockout HUES 1
adipocytes (one clone each; clone A) infected with SORT1-expressing or control lentivirus
and treated with or without insulin, all normalized to mean ratio in wild-type adipocytes
without insulin. N = 6.
(F) Immunocytochemistry for TUJ1 and ISL-1 in wild-type and knockout HUES 9 motor
neurons. Arrows indicate representative double-positive cells.
(G) Counts of wild-type and knockout HUES 9 (2 clones each, D and E) motor neurons
(TUJ1/ISL-1 double-positive cells) treated with BDNF vs. proBDNF. N = 12.
Error bars show s.e.m. from experiments with biological replicates. P values calculated with
unpaired t test. See also Figure S3, Figure S4, and Figure S5.
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Figure 4. AKT2 E17K is a Dominant, Activating Mutation
(A) Generation of AKT2 knockout and E17K knock-in hPSC clones with TALENs targeting
exon 2. The underline indicates the codon encoding E17K change. Boxes in wild-type
sequence indicate the TALEN binding sites. The box in the ssODN sequence indicates the
RsaI restriction site created by the synonymous mutation in blue; the nucleotide in red
indicates the missense mutation for E17K. Deletions and insertions in the two alleles of each
clone are indicated. The 15-bp insertion (asterisk) in clone A is 5’-
GACCTCCAGGTCCTG-3’.
(B) Western blot for AKT2 and AKT1 in wild-type, knockout, and E17K HUES 9 HLCs (A
and B for knockout; C and D for E17K).
Ding et al. Page 21
Cell Stem Cell. Author manuscript; available in PMC 2014 February 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(C) Immunocytochemistry for FoxO1 in HLCs (clones A and C) at baseline and after 15 min
insulin stimulation.
(D) Ratios of glucose production to secreted albumin mass (ELISA) in wild-type, knockout,
and E17K HUES 9 HLCs (two clones each; A and B for knockout; C and D for E17K)
treated with or without dexamethasone and forskolin with or without insulin, all normalized
to mean ratios in wild-type HLCs without additives. Left panel, N = 4; right panel, N = 2.
(E) Ratios of triglyceride content to total protein content in wild-type, knockout, and E17K
HUES 9 adipocytes (two clones each; A and B for knockout; C and D for E17K),
normalized to mean ratio in wild-type adipocytes. N = 5.
(F) Ratios of glucose uptake to total protein content in wild-type, knockout, and E17K
HUES 9 adipocytes (two clones each; A and B for knockout; C and D for E17K) treated
with or without insulin, all normalized to mean ratio in wild-type adipocytes without insulin.
N = 6.
(G) IL-8 and adiponectin mass measured by ELISA in media collected from wild-type,
knockout, and E17K HUES 9 adipocytes (two clones each; A and B for knockout; C and D
for E17K), normalized to mean levels from wild-type adipocytes. N = 4.
Error bars show s.e.m. from experiments with biological replicates. P values calculated with
unpaired t test. See also Figure S3 and Figure S6.
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Figure 5. PLIN1 Frameshift Mutations Produce Dominant-Acting and Truncated Proteins
(A) Generation of PLIN1 frameshift mutant hPSC clones with TALENs targeting exon 8.
Boxes indicate the TALEN binding sites. Deletions in the one allele of each clone are
indicated.
(B) Immunocytochemistry for perilipin and BODIPY in wild-type, PLIN1558 (clone A), and
PLIN1415 (clone B) adipocytes.
(C) Western blot for N-terminus of perilipin in wild-type, PLIN1558, and PLIN1415
adipocytes; arrow indicates truncated protein.
(D) Ratios of triglyceride content to total protein content in wild-type, PLIN1558, and
PLIN1415 adipocytes. N = 3.
(E) Ratios of lipolysis activity (as measured by glycerol release) to total triglyceride content
in wild-type, PLIN1558, and PLIN1415 adipocytes treated with or without 10 µM forskolin.
N = 4. Error bars show s.e.m. from experiments with biological replicates. P values
calculated with unpaired t test. See also Figure S7.
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